Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Liver Disease
- PMID: 31248551
- DOI: 10.1016/j.jacc.2019.04.052
Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Liver Disease
Abstract
Background: Advanced liver disease is known to increase the risk for bleeding and affects the hepatic clearance and metabolism of drugs. Subjects with active liver disease were excluded from pivotal clinical trials of direct oral anticoagulants (DOACs), so the evidence regarding the efficacy and safety of DOACs in patients with liver disease is lacking.
Objectives: The aim of this study was to compare DOACs with warfarin in patients with nonvalvular atrial fibrillation and liver disease.
Methods: Using the Korean National Health Insurance Service database, subjects with atrial fibrillation and active liver disease treated with oral anticoagulation were included (12,778 with warfarin and 24,575 with DOACs), and analyzed ischemic stroke, intracranial hemorrhage, gastrointestinal bleeding, major bleeding, all-cause death, and the composite outcome. Propensity score weighting was used to balance covariates between the 2 groups.
Results: DOACs were associated with lower risks for ischemic stroke (hazard ratio [HR]: 0.548; 95% confidence interval [CI]: 0.485 to 0.618), intracranial hemorrhage (HR: 0.479; 95% CI 0.394 to 0.581), gastrointestinal bleeding (HR: 0.819; 95% CI: 0.619 to 0.949), major bleeding (HR: 0.650; 95% CI: 0.575 to 0.736), all-cause death (HR: 0.698; 95% CI: 0.636 to 0.765), and the composite outcome (HR: 0.610; 95% CI: 0.567 to 0.656) than warfarin. Among the total study population, 13% of patients (n = 4,942) were identified as having significant active liver disease. A consistent benefit was observed in patients with significant active liver disease (HR for the composite outcome: 0.691; 95% CI: 0.577 to 0.827).
Conclusions: In this large Asian population with atrial fibrillation and liver disease, DOACs showed better effectiveness and safety than warfarin, which was consistent in those with significant active liver disease.
Keywords: atrial fibrillation; direct oral anticoagulant; liver disease; warfarin.
Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Comment in
-
Oral Anticoagulants in Liver Disease: Not Child's Play.J Am Coll Cardiol. 2019 Jul 2;73(25):3309-3311. doi: 10.1016/j.jacc.2019.05.009. J Am Coll Cardiol. 2019. PMID: 31248552 No abstract available.
-
Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Liver Disease.J Am Coll Cardiol. 2019 Nov 5;74(18):2329-2330. doi: 10.1016/j.jacc.2019.07.089. J Am Coll Cardiol. 2019. PMID: 31672194 No abstract available.
Similar articles
-
Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Low Body Weight.J Am Coll Cardiol. 2019 Mar 5;73(8):919-931. doi: 10.1016/j.jacc.2018.11.051. J Am Coll Cardiol. 2019. PMID: 30819360
-
Oral Anticoagulation in Asian Patients With Atrial Fibrillation and a History of Intracranial Hemorrhage.Stroke. 2020 Feb;51(2):416-423. doi: 10.1161/STROKEAHA.119.028030. Epub 2019 Dec 9. Stroke. 2020. PMID: 31813363
-
Effectiveness and Safety of Direct Oral Anticoagulants in an Asian Population with Atrial Fibrillation Undergoing Dialysis: A Population-Based Cohort Study and Meta-Analysis.Cardiovasc Drugs Ther. 2021 Oct;35(5):975-986. doi: 10.1007/s10557-020-07108-4. Epub 2020 Nov 19. Cardiovasc Drugs Ther. 2021. PMID: 33211254
-
Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.Circulation. 2018 Oct 2;138(14):1402-1411. doi: 10.1161/CIRCULATIONAHA.117.031457. Circulation. 2018. PMID: 29794081
-
Efficacy and Safety of Direct Oral Anticoagulants vs Warfarin in Patients with Chronic Kidney Disease and Dialysis Patients: A Systematic Review and Meta-Analysis.Clin Drug Investig. 2021 Apr;41(4):341-351. doi: 10.1007/s40261-021-01016-7. Epub 2021 Mar 11. Clin Drug Investig. 2021. PMID: 33709339
Cited by
-
Efficacy and Safety of Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Liver Disease: a Meta-Analysis and Systematic Review.Cardiovasc Drugs Ther. 2021 Dec;35(6):1205-1215. doi: 10.1007/s10557-020-07065-y. Epub 2020 Sep 3. Cardiovasc Drugs Ther. 2021. PMID: 32880804
-
Stroke Prevention in Atrial Fibrillation: A Scientific Statement of JACC: Asia (Part 2).JACC Asia. 2022 Aug 23;2(5):519-537. doi: 10.1016/j.jacasi.2022.06.004. eCollection 2022 Oct. JACC Asia. 2022. PMID: 36624790 Free PMC article. Review.
-
Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with advanced chronic kidney and liver diseases.Eur Heart J Suppl. 2022 Feb 14;24(Suppl A):A11-A18. doi: 10.1093/eurheartj/suab154. eCollection 2022 Feb. Eur Heart J Suppl. 2022. PMID: 35185405 Free PMC article.
-
Effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in atrial fibrillation patients with liver disease: a systematic review and meta-analysis.Front Pharmacol. 2025 Jul 14;16:1620394. doi: 10.3389/fphar.2025.1620394. eCollection 2025. Front Pharmacol. 2025. PMID: 40727096 Free PMC article.
-
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.Circulation. 2024 Jan 2;149(1):e1-e156. doi: 10.1161/CIR.0000000000001193. Epub 2023 Nov 30. Circulation. 2024. PMID: 38033089 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical